Failure to Satisfy Listing Rule Form 8 K

As reported by Celularity Inc., or Celularity, in its Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission, or SEC, on November 15, 2024, Celularity was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 ("Q3 2024 Form 10-Q"), within the prescribed time period. The extension provided under Rule 12b-25 expired on November 19, 2024.

On November 21, 2024, the Company informed the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") that it failed to timely file its Q3 2024 Form 10-Q within the extension period provided by Rule 12b-25 because the Company had not yet completed the preparation of the financial statements. On November 21, 2024, Nasdaq provided formal notice to the Company that as a result of the Company's failure to timely file its Q3 2024 10-Q, it no longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols "CELU" and "CELUW", respectively.

The Company is required to submit to Nasdaq a plan to regain compliance within 60 calendar days, or by January 20, 2025, and if accepted, the Company has a period of 180 calendar days from the Q3 2024 Form 10-Q due date, or until May 13, 2025, to implement the plan to regain compliance. The Company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period. However, there can be no assurance that the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements.